Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 18/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16742006 | 1.00 | DHODH (1.00) | DHODHMEN1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL16742075 | 0.87 | DHODH (1.00) | DHODHMEN1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL16742077 | 0.87 | DHODH (1.00) | DHODHMEN1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL5914883 | 0.82 | DHODH (0.75) | DHODHMEN1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL5914886 | 0.82 | DHODH (0.75) | DHODHMEN1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL5914909 | 0.82 | DHODH (0.71) | DHODHMEN1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL5914908 | 0.82 | DHODH (0.71) | DHODHMEN1ALDH1A1KMT2ACYP1A2 | |
| SCHEMBL16741986 | 0.74 | DHODH (1.00) | DHODH | |
| SCHEMBL16741987 | 0.74 | DHODH (1.00) | DHODH | |
| SCHEMBL5914881 | 0.74 | DHODH (0.64) | DHODHMEN1ALDH1A1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| EP-3071199-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Genzyme Corporation (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015077535-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | DHODH 1/4885MEN1 4519/4885ALDH1A1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.